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Population-Based Trends in High-Grade Cervical Lesions in the
Early Human Papillomavirus Vaccine Era in the United States
Susan Hariri, PhD1; Michelle L. Johnson, MPH1; Nancy M. Bennett, MD, MS2; Heidi M. Bauer, MD, MS, MPH3;
Ina U. Park, MD, MS3; Sean Schafer, MD4; Linda M. Niccolai, PhD5; Elizabeth R. Unger, MD, PhD6;
Lauri E. Markowitz, MD1; and HPV-IMPACT Working Group

BACKGROUND: Cervical intraepithelial neoplasia grade 2, 3, and adenocarcinoma in situ (CIN21) lesions can be monitored as early indicators of human papillomavirus (HPV) vaccine impact. Changes to screening utilization will affect observed reductions in CIN21 rates
and complicate the interpretation of vaccine impact. METHODS: From 2008 to 2012, 9119 cases of CIN21 among 18- to 39-year-old
residents of catchment areas in California, Connecticut, New York, and Oregon were reported to the HPV-IMPACT Project, a sentinel
system for monitoring the population impact of HPV vaccine. Age-stratified CIN21 incidence rates were calculated for each catchment. Annual cervical screening was estimated for California, New York, and Oregon catchments with administrative and survey data.
The Cochran-Armitage test was used to examine trends. RESULTS: From 2008 to 2012, the incidence of CIN21 significantly
decreased among 18- to 20-year-olds (California, from 94 to 5 per 100,000 women; Connecticut, from 450 to 57 per 100,000 women;
New York, from 299 to 43 per 100,000 women; and Oregon, from 202 to 37 per 100,000 women; Ptrend < .0001) and among 21- to
29-year-olds in Connecticut (from 762 to 589 per 100,000 women) and New York (from 770 to 465 per 100,000 women;
Ptrend < .001); rates did not differ among 30- to 39-year-olds. During the same period, screening rates also declined, with the largest
decreases among 18- to 20-year-olds (from 67% in Oregon to 88% in California) and with smaller declines among 21- to 29-year-olds
(13%-27%) and 30- to 39-year-olds (3%-21%). CONCLUSIONS: The declines in CIN21 detection in young women were likely due to
reduced screening but could also reflect the impact of vaccination. These data illustrate challenges in interpreting CIN21 ecologic
trends in the new era of cervical cancer prevention and emphasize the importance of information such as HPV types detected in
C 2015 American Cancer Society.
lesions to assess the impact of HPV vaccine on cervical precancers. Cancer 2015;121:2775-81. V
KEYWORDS: cervical cancer screening, cervical intraepithelial neoplasia (CIN), cervical precancers, high-grade cervical lesions, human
papillomavirus (HPV), human papillomavirus vaccine effectiveness, human papillomavirus vaccines.

INTRODUCTION
Persistent infection with oncogenic types of human papillomavirus (HPV) can cause high-grade cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (CIN21); these asymptomatic lesions can, over decades, progress to invasive
cervical cancer if they are left untreated.1,2 Two vaccines against HPV 16 and HPV 18, types that are responsible for 70%
of cervical cancers and >50% of CIN21 lesions, are available in the United States, one since 2006.3 In clinical trials,
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both vaccines demonstrated high prophylactic efficacy
against CIN21 lesions, and this was the main endpoint
used for vaccine licensure.4,5
In countries with widespread cervical cancer screening programs, CIN21 lesions can be monitored as early
indicators of the population impact of HPV vaccination.
Less than a decade since the introduction of HPV vaccination, reductions in CIN21 have been observed in countries such as Australia and Denmark where vaccination
programs have included catch-up vaccine for older
women and have achieved high vaccination coverage
shortly after implementation.6-8 Because CIN21 is detectable only through routine cervical cancer screening,
changes to screening utilization will contribute to
observed reductions in CIN21 rates and complicate the
interpretation of vaccine impact. To account for this,
studies in Denmark and Australia have examined CIN21
rates in vaccinated and unvaccinated individuals by linking disease, screening, and immunization data across regional or national population-based registries.6-8
Demonstrating vaccine impact on CIN21 is more
challenging in the United States because of incomplete
reporting of adolescent vaccination to state-based immunization registries, a lack of national screening registries,
and, importantly, evolving cervical cancer screening practices. Over the past decade, the recommended age for initiating cervical cancer screening has been raised to 21
years, and screening intervals have been increased, particularly if HPV-based cotesting is used.9 The objectives of
this ecologic study were to 1) describe trends in CIN21
diagnosis rates in different geographic areas in the United
States with population-based data from the first 5 years of
the HPV-IMPACT Project10 and 2) examine cervical cancer screening rates in the women residing in the HPVIMPACT catchment areas.

MATERIALS AND METHODS
System Description

HPV-IMPACT was established in 2008 to monitor the
impact of HPV vaccination on CIN21 through
population-based laboratory surveillance. The project is
an ongoing collaboration between the Centers for Disease
Control and Prevention and 5 sites in the Emerging Infections Program Network. Catchment areas include 8 contiguous cities in northwest Alameda County, Calif.; New
Haven County, Conn.; Monroe County, NY; Davidson
County, Tenn.; and a contiguous region of Washington
and Multnomah Counties, Ore. (which includes the city
of Portland). The total population of women who were
2776

18 years old or older ranged from 230,000 to 330,000 at
each participating site according to the 2010 US Census
data. This project was reviewed by the US Centers for
Disease Control, the Oregon Health Authority Public
Health Division, and the institutional review boards of
Yale University, University of California Berkeley, University of California San Francisco, Vanderbilt University,
Alameda County Medical Center, Kaiser Permanente,
Unity Health System, and Rochester General Hospital,
and it was determined to be exempt from institutional
review board approval because the activity constituted
routine disease surveillance for disease control program
and policy purposes. The project was approved by the
State of California Committee for the Protection of
Human Subjects. Informed consent was not required
from any reviewing/approving institution. All patient
records and information were anonymized and deidentified before analysis.
CIN21 Case Ascertainment

Local and commercial laboratories serving the catchment
areas reported cases of histologically confirmed CIN21
diagnosed in adult (18 years) female residents of the
areas. Cases were identified through electronic health record searches or manual chart reviews. Classification systems and nomenclature for high-grade cervical lesions
that were in use during the monitoring time period were
included in the search criteria to identify cases. Because
CIN21 is not a nationally notifiable condition, a variety
of methods were undertaken to enhance the completeness
of the reporting; these included the establishment of mandated reporting in Connecticut (since 2008) and Oregon
(since 2012). Laboratories that did not report before the
mandate in Oregon agreed to provide retrospective data
from 2008. At the time of this study, legal and logistical
challenges prevented the institution of mandates in New
York and California, but reporting was ensured through
the building of strong relationships with the laboratories
and through the engagement of community support. In
addition, laboratory audits were performed at all sites to
evaluate reporting completeness. The number of reporting laboratories ranged from 4 in New York to 29 in Connecticut; however, more than 80% of the cases were
reported by 3 to 5 laboratories in each area. Reports were
deduplicated within and between reporting laboratories.
Reported diagnoses were grouped by histologic grade
into CIN2, CIN2/3 (grade not discriminated), CIN3, and
adenocarcinoma in situ with or without CIN. CIN21
diagnoses reported for the same individual within 6 months
of the initial diagnosis date were considered to be related to
Cancer
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the same CIN21 lesion, and the case was classified according to the highest grade diagnosis within the 6-month period. For women diagnosed with CIN21 between the ages
of 18 and 39 years, attempts were made to collect the date
of birth, race/ethnicity, health insurance status, and clinical
and HPV vaccination history. Sources of data differed
according to the type of information collected and availability, and they included outpatient provider medical
records, administrative and claims databases, immunization registries, and patient interviews.
Study Population

The analysis was restricted to participants aged 18 to 39
years who were diagnosed with CIN21 between January
2008 and December 2012 in 4 of 5 catchment areas with
complete reporting for all years: California, Connecticut,
New York, and Oregon. Tennessee was excluded from this
analysis because of incomplete reporting for some years.
Ages were categorized into 3 age groups: 18 to 20, 21 to 29,
and 30 to 39 years. Self-reported race/ethnicity was used to
classify women into non-Hispanic white, non-Hispanic
black, Hispanic, and Asian groups; all other reported races
were combined into an other category, and this field was
indicated as missing for those without race/ethnicity information. The vaccination status among those who were ageeligible for vaccination (ie, aged 11-26 years at some point
during the study period) was classified as vaccinated (receipt
of at least 1 dose), not vaccinated, or unknown.
Cervical Cancer Screening Estimation

Aggregate or individual-level data were used to estimate
cervical cancer screening rates among female residents
aged 18 to 39 years for 3 project sites: California, New
York, and Oregon. Screening estimates for the catchment
population were not available for Connecticut. In California and Oregon, a variety of data sources, including
national and state-based surveys and administrative data,
were used to calculate a weighted estimate of screening by
age group. Women in the catchment area were divided
into 2 groups based on insurance status (insured or uninsured), and annual screening rates were obtained for each
group with data from the American Community Survey
and the Behavioral Risk Factor Surveillance Survey to estimate the relative proportions and the differences in
screening rates between the groups. The insured and uninsured groups were then combined to estimate overall annual screening rates by age group (18-20, 21-29, and 3039 years), which were adjusted for insurance status.
New York obtained deidentified cervical cancer
screening reports from each of 3 local cytopathology
Cancer
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laboratories serving Monroe County, NY. Each report
was deduplicated within the laboratory and included the
patient’s age and the results of the first screen in a given
calendar year. Reports across the 3 laboratories were combined and categorized into specified age groups. Screening
rates were estimated with 2010 US Census data.
CIN21 Incidence Estimation

CIN21 incidence was determined using the date of the
first diagnosis reported within a 6-month period. Any
subsequent reports from the same person during the 6
months succeeding the incident were excluded. Annual
CIN21 incidence rates were calculated with 2010 US
Census data. Age-adjusted and age-specific CIN21 incidences were estimated for each catchment area. Incidence
rates are reported per 100,000 female population.
Percent changes and 95% confidence intervals were
calculated for the initial and final years. The CochraneArmitage test for linear trends was used to examine the
statistical significance of CIN21 incidence trends. Twosided statistical tests were considered significant at the a
level of .05.
RESULTS
CIN21 Diagnosis by Population Characteristics

From 2008 to 2012, a total of 11,394 CIN21 diagnoses among adult women aged 18 years and older were
reported to 4 HPV-IMPACT catchment areas; 9119
(80.0%) were aged 18 to 39 years and are included in
this report. CIN2 was the most common histologic diagnosis reported overall (50.8%) and in all catchment
areas; the incidence ranged from 41.1% in California to
57.9% in Connecticut (Table 1). CIN3 constituted
30.9% of diagnoses overall and was highest in California (36.2%). Adenocarcinoma in situ, with or without
CIN, accounted for only 2.3% of diagnoses. The majority of CIN21 diagnoses (59.2%) occurred in women
aged 21 to 29 years; 18- to 20-year-olds represented
only 4.6% of all reported cases. Among the 81.9% with
known race/ethnicity, 61.1% were non-Hispanic white,
14.7% were non-Hispanic black, 15.9% were Hispanic,
and 4.8% were Asian. Private insurance was most commonly reported overall (66.2%), and only 3.5%
reported no insurance. The HPV vaccination status was
available for 2991 of 6299 women with CIN21
(47.5%) who were age-eligible for vaccination during
the analysis time period. The proportion of those for
whom the vaccination history was ascertained
ranged by site from 23.2% in California to 62.8% in
New York.
2777
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TABLE 1. Selected Characteristics Among Women Aged 18 to 39 Years Who Were Diagnosed With CIN21
(HPV-IMPACT, 2008-2012)
Total
(n 5 9119)
Characteristic
Diagnosis
CIN2
CIN2/3
CIN3
AIS 6 CIN
Age
18-20 y
21-29 y
30-39 y
Race/ethnicity
Non-Hispanic white
Non-Hispanic black
Hispanic
Asian
Other
Missing
Insurance
Private
Publica
Uninsuredb
Other
Missing
Vaccination statusc
Vaccinated (1dose)
Not vaccinated
Unknown
Not age-eligible

California
(n 5 1748)

Connecticut
(n 5 2971)

New York
(n 5 2301)

Oregon
(n 5 2099)

n

%

n

%

n

%

n

%

n

%

4637
1452
2819
211

50.8
15.9
30.9
2.3

719
363
632
34

41.1
20.8
36.2
1.9

1720
357
860
34

57.9
12.0
28.9
1.1

1155
413
667
66

50.2
17.9
29.0
2.9

1043
319
660
77

49.7
15.2
31.4
3.7

417
5400
3302

4.6
59.2
36.2

34
937
777

1.9
53.6
44.5

173
1782
1016

5.8
60.0
34.2

150
1468
683

6.5
63.8
29.7

60
1213
826

2.9
57.8
39.4

4564
1097
1185
356
267
1650

61.1
14.7
15.9
4.8
3.6
—

437
258
329
193
60
471

34.2
20.2
25.8
15.1
4.7
—

1419
379
525
49
71
528

58.1
15.5
21.5
2.0
2.9
—

1504
389
185
43
37
143

69.7
18.0
8.6
2.0
1.7
—

1204
71
146
71
99
508

75.7
4.5
9.2
4.5
6.2
—

5009
2037
267
251
1555

66.2
26.9
3.5
3.3
—

1039
402
13
12
282

70.9
27.4
0.9
0.8
—

1615
956
88
50
262

59.6
35.3
3.2
1.8
—

1324
471
56
93
357

68.1
24.2
2.9
4.8
—

1031
208
110
96
654

71.3
14.4
7.6
6.6
—

1452
1539
3308
2820

23.1
24.4
52.5
—

127
125
834
662

11.7
11.5
76.8
—

555
672
875
869

26.4
32.0
41.6
—

568
513
641
579

33.0
29.8
37.2
—

202
229
958
710

14.5
16.5
69.0
—

Abbreviations: CIN21, cervical intraepithelial neoplasia grade 2, 3, and adenocarcinoma in situ; AIS, adenocarcinoma in situ; CIN, cervical intraepithelial neoplasia (numbers following “CIN” indicate the grade).
a
Includes Medicaid (state assistance), Medicare, Indian Health Services, and Military/Veterans Administration.
b
Includes documented self-pay or no coverage.
c
Excludes those who were not eligible for vaccination because of age.

CIN21 Incidence

Age-adjusted rates of newly diagnosed CIN21 per
100,000 significantly decreased between 2008 and 2012
in Connecticut (from 543 to 407) and New York (from
505 to 344; Ptrend < .0001). During the same time period,
there was a nonsignificant increase in the incidence of
CIN21 in California (from 277 to 293) and Oregon
(from 325 to 344).
Reported incidence rates varied across the 4 catchment
areas for every year included in the analysis (Fig. 1). For all
years, rates were highest in Connecticut, which was followed
by New York, Oregon, and California. The age-adjusted
incidence was 1.96 times as high in Connecticut versus the
rate in California in 2008, but by 2012, the incidence in
Connecticut was only 1.39 times that of California.
CIN21 incidence rates for the 4 catchment areas are
presented by age group and year in Table 2. There was a
sharp and consistent decrease among 18- to 20-year-old
women across all sites between 2008 and 2012; the
2778

decrease in incidence ranged from 82% in Oregon to
94% in California (Ptrend < .0001 for all areas). Incidence
trends were not consistent across catchment areas in the
older age groups in the same 5-year period. In the 21- to
29-year-old group, the CIN21 incidence significantly
decreased by 40% in New York and 23% in Connecticut
(P < .001) but increased slightly in Oregon (12%; 95%
confidence interval, 26% to 34%) and California (13%;
95% confidence interval, 27% to 37%). Among those
aged 30 to 39 years, incidence rates did not change significantly in any of the catchment areas.
Trends in CIN21 Diagnosis and Screening
Utilization

Figure 2 displays annual CIN21 incidence and screening
rates by age group in the 3 catchment areas for which
screening rates could be estimated. Among 18- to 20year-olds, both CIN21 and screening rates decreased substantially in all catchment areas; screening rates decreased
Cancer
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67% in Oregon, 80% in New York, and 88% in California. Although the proportion of women screened in this
age group differed across catchment areas in the first year
of the study (from 41% in New York to 15% in Oregon),
screening rates declined to less than 10% in all areas by
2012, with the steepest decline occurring between 2009
and 2010. Overall CIN21 rate reductions exceeded estimated declines in screening in this age group by 7% in
California, 5% in New York, and 15% in Oregon.

Figure 1. Age-adjusted CIN21 incidence (per 100,000)
among adult women aged 18 to 39 years by catchment area
and year (HPV-IMPACT, 2008-2012). *Rates were ageadjusted to the 2010 US Census female population in 5-year
age groups (18-19, 20-24, 25-29, 30-34, and 35-39 years).
CIN21 indicates cervical intraepithelial neoplasia grade 2, 3,
and adenocarcinoma in situ.

Screening rates decreased among women aged 21 to
29 years during the same time period, but to a smaller
degree. Relative decreases were 13% in Oregon, 26% in
New York, and 27% in California. In New York, there was
a corresponding and larger decline (40%) in the CIN21
incidence during the 5-year period. No CIN21 decreases
were observed in California or Oregon in this age group. In
the 30- to 39-year-old age group, there were inconsistent
changes in both CIN21 and screening rates. Overall,
screening decreased in all 3 catchment areas (3% in California, 18% in New York, and 21% in Oregon), whereas the
CIN21 incidence remained largely unchanged.
DISCUSSION
This population-based study describes the CIN21 incidence in women across multiple geographic areas in the
United States and examines CIN21 incidence trends in
the first few years since the introduction of HPV vaccine.
We found striking differences in the baseline incidence of
CIN21 diagnoses across the 4 catchment areas. In the
first year of the study, the CIN21 burden in Connecticut
and New York was approximately twice that in Oregon
and California. Site differences diminished over the next 4
years as CIN21 rates significantly decreased in Connecticut and New York but remained the same or slightly
increased in the other 2 catchment areas. Differences in
screening utilization among health care providers may be
partially responsible for the large geographic variability in
CIN21 rates. California and Oregon, areas with the lowest CIN21 incidence and lower screening rates, tended to
have higher population enrollment in managed care

TABLE 2. Incidence of CIN21 (per 100,000) by Age Group, Year, and Catchment Area (HPV-IMPACT, 20082012)
2008
Age
18-20 y
California
Connecticut
New York
Oregon
21-29 y
California
Connecticut
New York
Oregon
30-39 y
California
Connecticut
New York
Oregon

2009

2010

2011

2012
% Change (2008-2012):
% (95% Confidence Interval)

n

Rate

n

Rate

n

Rate

n

Rate

n

Rate

18
87
56
22

94
450
299
202

10
39
42
20

52
202
224
183

3
22
32
10

16
114
171
92

2
14
12
4

10
72
64
37

1
11
8
4

5
57
43
37

294
287
286
282

(299,
(293,
(293,
(294,

192
397
363
232

348
762
770
447

173
367
350
252

314
704
743
486

176
342
276
237

319
656
586
457

180
369
260
232

326
708
552
447

216
307
219
260

392
589
465
501

13
223
240
12

(27, 37)
(233, 210)
(249, 229)
(26, 34)

160
198
142
137

270
368
321
241

153
204
146
180

258
379
330
317

133
212
122
163

224
394
276
287

157
217
129
187

265
403
291
330

174
185
144
159

293
343
325
280

9
27
1
16

258)
276)
270)
247)

(212, 35)
(224, 14)
(220, 28)
(28, 46)

Abbreviation: CIN21, cervical intraepithelial neoplasia grade 2, 3, and adenocarcinoma in situ.
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Figure 2. CIN21 incidence (per 100,000 women) and proportions screened by age group, year, and catchment area
(HPV-IMPACT, 2008-2012). CIN indicates cervical intraepithelial neoplasia; CIN21, cervical intraepithelial neoplasia grade
2, 3, and adenocarcinoma in situ.

organizations, which were among the first to implement
new recommendations to extend screening intervals.9 The
gradual adoption of new screening guidelines by a wider
2780

array of providers may explain the narrowing gap in rates
and larger declines in Connecticut and New York, where
traditional fee-for-service health systems predominated.
Another possible reason for the observed variability in
CIN21 incidence across sites could be differences in population characteristics such as sexual behaviors and smoking,
which may differentially influence the risk for CIN21 in
these populations. Finally, differences in vaccination coverage may also play a role, although this is unlikely because
the greatest variability in incidence was in the first year
when few adult women with CIN21 would have been vaccinated, and site differences diminished over time as vaccination coverage increased in this population.
We found a dramatic and consistent decrease in
CIN21 incidence in all catchment areas among 18- to
20-year-old women. By 2012, CIN21 diagnoses in this
age group had declined to 10 or fewer cases per 100,000
at all 4 sites. The observed declines in this age group were
likely due to wide-scale implementation of new guidelines
that recommend cervical cancer screening begin at the age
of 21 years. This is reflected in the substantial decrease in
cervical cancer screening that we found in this age group
during the same time period. However, the larger
decreases in CIN21 incidence with respect to declines in
screening suggest the possible impact of the vaccine on
reducing the true burden of CIN21 in this age group.
Trends in CIN21 rates in the older age groups were
inconsistent and more difficult to interpret. In particular,
we did not observe any decreases in CIN21 incidence in
the 20- to 29-year-age groups in California and Oregon despite the sustained declining trends in screening. An analysis of more years of data is ongoing to determine any
emerging trends. The impact of the vaccine on CIN21
trends in this age group should become clearer over time as
more women in this age group receive HPV vaccine at
younger ages. However, decreases in the measured incidence due to vaccination may be confounded by continued
changes in screening practices, such as the recent approval
of an HPV-based test for the primary screening of women
who are 25 years old or older. Among women aged 30 to
39 years, CIN21 rates were similarly inconsistent with no
discernible trends over the 5-year study period.
This analysis demonstrates the challenges in examining the ecologic effect of HPV vaccination on CIN21 incidence trends during a time of concurrent changes to
screening recommendations, even in geographically welldefined populations. Although our data suggest that less
screening in the youngest age group likely had the largest
impact on the observed declines in CIN21 rates, some of
the observed decreases may be attributable to vaccination.
Cancer
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However, it was not possible to quantify the relative contribution of vaccination in these populations. Although a
complete and accurate vaccination history was not obtainable for the majority of this study population, national survey data indicate that self-reported HPV vaccination
coverage (1 dose) in women aged 19 to 26 years was low
during our study period and ranged from 11.6% in 2008
to 34.5% in 2012.11
To assist with the interpretation of observed CIN21
trends, we identified all available data sources with which
age-stratified annual screening rates in the catchment population could be estimated. However, there were insufficient
data to allow estimation in one project area, and the use of
disparate data sources and estimation methodologies prevented valid comparisons across the other 3 areas. Despite
these limitations, the fact that our findings were similar to
results obtained from the only population-based screening
registry in the United States is reassuring.12 In that study,
Cuzick et al12 found a significant 61% decrease in screening
in females aged 15 to 20 years from 22.4% in 2008 to 8.7%
in 2011. Finally, changes to CIN21 terminology and coding that occurred during the study period may have also
affected the completeness of the reporting. However, extensive audits of reporting laboratories using broad search criteria did not suggest differential or underreporting over time.
To our knowledge, this is the first examination of
trends in CIN21 diagnosis in multiple populations of US
women in the new era of cervical cancer prevention. These
results demonstrate large and uniform reductions in the
CIN21 incidence in young women aged 18 to 20 years as
well as more variable declines in women aged 20 to 29
years, which may be due to a combination of new screening guidelines and HPV vaccine introduction. Importantly, our data illustrate the challenges in assessing HPV
vaccine impact on cervical precancers in the United States
and emphasize the importance of additional information
such as the types of HPV detected in these lesions to assist
in this determination.13
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